Cytotheryx Secures Lead Investor for $60M Series A; Confirms Debt Financing to Expand Facilities
Cytotheryx’s Series A financing, alongside strategic debt funding, will advance its cell therapy programs toward clinical development and support GMP manufacturing scale-up. ROCHESTER, Minn., Jan. 12, 2026 /PRNewswire/ — Cytotheryx, Inc. , a preclinical cell therapy company developing cell-based…